Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Allogene Therapeutics Inc
(NQ:
ALLO
)
3.460
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
3.460
Bid (Size)
3.450 (1)
Ask (Size)
3.550 (5)
Prev. Close
3.460
Today's Range
3.460 - 3.460
52wk Range
2.230 - 6.870
Shares Outstanding
142,183,418
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
To The Moon! A Look Inside An ETF Focused On Companies At The Cutting Edge Of Innovation
April 18, 2024
Via
Benzinga
Topics
ETFs
3 Meme Stocks to Sell and Replace With Meme Coins
April 11, 2024
For investors who want to avoid losses, sell or avoid certain meme stocks that are on the radar for potential sell-offs.
Via
InvestorPlace
Performance
YTD
-4.42%
-4.42%
1 Month
-21.18%
-21.18%
3 Month
+8.12%
+8.12%
6 Month
+16.11%
+16.11%
1 Year
-29.82%
-29.82%
More News
Read More
Allogene Therapeutics Announces Q2 Investor Conference Participation
April 09, 2024
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
ALLO Stock Earnings: Allogene Therapeutics Misses EPS, Beats Revenue for Q4 2023
March 14, 2024
Via
InvestorPlace
Recap: Allogene Therapeutics Q4 Earnings
March 14, 2024
Via
Benzinga
Allogene Therapeutics Earnings Preview
March 13, 2024
Via
Benzinga
Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
March 14, 2024
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Earnings Scheduled For March 14, 2024
March 14, 2024
Via
Benzinga
Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease
March 12, 2024
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update
March 05, 2024
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care Conference
February 28, 2024
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in Asia
February 16, 2024
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
CymaBay Therapeutics, ContextLogic, Snap And Other Big Stocks Moving Higher On Monday
February 12, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
January 16, 2024
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Cell Therapy Focused Allogene Therapeutics' Resource Prioritization A Bold Move, Says Analyst
January 05, 2024
Via
Benzinga
Why Applied Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session
January 05, 2024
Via
Benzinga
Allogene Layoffs 2024: What to Know About the Latest ALLO Job Cuts
January 05, 2024
Via
InvestorPlace
Topics
Workforce
Exposures
Layoff
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
January 05, 2024
Via
InvestorPlace
Franklin Covey Shares Fall After Q1 Results, Joins Theravance Biopharma, Voyager Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session
January 05, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Thursday's After-Market Session
January 04, 2024
Via
Benzinga
Allogene Therapeutics and Foresight Diagnostics Announce Partnership to Develop MRD-based In-Vitro Diagnostic for Use in ALPHA3, the First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma
January 04, 2024
From
Allogene Therapeutics, Inc.; Foresight Diagnostics
Via
GlobeNewswire
Allogene Therapeutics Announces 2024 Platform Vision to Redefine the Future of CAR T Led by ALPHA3, the Industry's First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma
January 04, 2024
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics to Host Conference Call Previewing its 2024 Platform Vision and Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Why Longboard Pharmaceuticals Shares Are Trading Higher By Around 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
January 02, 2024
Via
Benzinga
Why AAR Shares Are Trading Lower By 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
December 22, 2023
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.